Ex Vivo Drug Response Platform From KYAN Shows Clinical Utility in Non-Hodgkin Lymphoma Patients
Optim.AI™ accurately predicted response in prospective cohort; results published in JCO Precision Oncology, a journal of ASCO SINGAPORE, July 27, 2025 /EINPresswire.com/ -- A prospective clinical study published in JCO Precision Oncology, a …